Pharmaceutical laboratories are banking on vaccinating seniors

Pharmaceutical laboratories are banking on vaccinating seniors
Pharmaceutical laboratories are banking on vaccinating seniors

The supply of vaccines for those over 60 is increasing. But this population is still reluctant to protect themselves.

In Wavre in Belgium, employees who check the quality of vaccines leaving the factory with the naked eye have become accustomed to scrutinizing new formulas. Alongside bottles and syringes intended for children, such as Rotarix (against certain gastroenteritis), those intended for the elderly occupy an increasing place.

The largest vaccine factory in the world, a real city in the town of Wavre and owned by the British giant GSK, has reorganized to ramp up and produce new vaccines intended for adults. This factory, where two thirds of the world’s GSK vaccines pass, now produces Shingrix, which protects seniors against shingles, and Arexvy, a vaccine against the respiratory syncytial virus (RSV) which causes bronchiolitis in elderly people. babies, but also severe complications in those over 60 years old.

Vulnerability of the elderly

A few years ago, our vaccines were mainly aimed at children, because that was where most of the unmet need was

This article is reserved for subscribers. You have 83% left to discover.

Do you want to read more?

Unlock all items immediately.

Already subscribed? Log in

-

-

PREV Emergency mobilization to fight cholera in Mayotte
NEXT Vaccination against papillomavirus: Deux-Sèvres in progress